News and analysis on Türkiye’s pharmaceutical and biotechnology industries, including drug development, manufacturing, investment, regulation and life sciences.
The U.S. Food and Drug Administration has approved the RAS inhibitor daraxonrasib for adult patients with metastatic pancreatic ductal adenocarcinoma…
A single-dose PCSK9 base editing therapy has produced substantial and sustained reductions in LDL cholesterol in an early-stage clinical trial…
The mid-year update to 2026 Drugs to Watch shows how quickly the pharmaceutical pipeline can change. By July, several therapies…
Five high-profile FDA drug approvals to watch in 2026 illustrate a broader shift toward treatments that may reduce the burden…
Johnson & Johnson has reached a proposed $5.5 billion settlement covering roughly 76,000 remaining ovarian cancer claims linked to its…
Pharmaceutical giant Eli Lilly has signed a deal worth up to €2.39 billion with Insilico Medicine, a company that uses…
Turkey has reached a milestone in pharmaceutical innovation after its first homegrown drug candidate successfully completed a Phase 1 clinical…
MedTurkiye360 is the trusted multi-language source for Turkish healthcare.
MedTurkiye360 is an independent industry news platform covering Turkiye’s healthcare ecosystem, from hospitals and medical tourism to pharmaceuticals, MedTech, investments and health policy.”